Inovio Shareholders Urged to File Lawsuit Over Securities Fraud

Deadline Alert: Investors Who Lost Money on Inovio Stock Encouraged to Contact Law Firm About Class Action

Mar. 13, 2026 at 5:48pm

Got story updates? Submit your updates here. ›

Glancy Prongay Wolke & Rotter LLP is reminding investors of the upcoming April 7, 2026 deadline to file a lead plaintiff motion in a class action lawsuit against Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The lawsuit alleges that Inovio made materially false and misleading statements about its business, operations, and prospects related to its INO-3107 treatment and CELLECTRA device, which resulted in investor losses.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from publicly traded companies. Investors who suffered losses due to Inovio's alleged misrepresentations may be able to recover those losses through the class action lawsuit.

The details

The lawsuit alleges that Inovio failed to disclose that its CELLECTRA device had manufacturing issues, which made it unlikely that Inovio would submit the INO-3107 Biologics License Application (BLA) to the FDA by the promised timeline. The lawsuit also claims Inovio overstated the prospects for INO-3107's regulatory approval and commercialization.

  • On August 8, 2024, Inovio released its Q2 2024 financial results, revealing a 'manufacturing issue' with CELLECTRA that would delay the INO-3107 BLA submission.
  • On December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline, rather than the accelerated review timeline the company had touted.

The players

Inovio Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing DNA medicines to treat and prevent infectious diseases, cancer, and other diseases.

Glancy Prongay Wolke & Rotter LLP

A law firm representing investors in the class action lawsuit against Inovio.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on April 7, 2026 whether to appoint a lead plaintiff in the class action lawsuit against Inovio.

The takeaway

This case highlights the importance of accurate and timely disclosures by publicly traded companies. Investors who suffered losses due to Inovio's alleged misrepresentations may be able to recover those losses through the class action lawsuit, underscoring the role of legal action in holding companies accountable for misleading investors.